Vantage BioTrials - Vantage Biotrials https://vantagebiotrials.com/fr Contract Research Organization (CRO) implementing Risk-Based Management through the use of Quality by Design (Qbd) methodologies. Mon, 03 Aug 2026 15:25:37 +0000 fr-CA hourly 1 https://wordpress.org/?v=7.1.3 https://vantagebiotrials.com/wp-content/uploads/2024/03/cropped-favicon-VBT-32x32.png Vantage BioTrials - Vantage Biotrials https://vantagebiotrials.com/fr 32 32 Operational Excellence in Clinical Trials Summit | September 23 – 24, 2026 https://vantagebiotrials.com/fr/operational-excellence-in-clinical-trials-summit-september-23-24-2026/?utm_source=rss&utm_medium=rss&utm_campaign=operational-excellence-in-clinical-trials-summit-september-23-24-2026 Mon, 03 Aug 2026 15:18:33 +0000 https://vantagebiotrials.com/?p=5334 Vantage BioTrials to Present at the 10th Operational Excellence in Clinical Trials Summit Join Vatché Bartekian for a Featured Presentation on Quality-by-Design and Risk-Based Governance September 23–24, 2026 | Courtyard Toronto Downtown | Toronto, Canada Vantage BioTrials is pleased to announce that Vatché Bartekian, President, has been invited to speak at the 10th Operational Excellence in Clinical Trials Summit (OECT Summit Canada 2026), one of Canada’s leading conferences dedicated to advancing innovation and operational excellence in clinical research. The summit brings together leaders in Clinical Operations, Clinical Development, Project Management, Study Feasibility, Site Management, and Vendor Oversight to explore strategies that improve clinical trial performance. Featured Presentation Quality by Design Begins Before Study Start-Up: Embedding Risk-Based Governance into CRO and Vendor Selection Quality-by-Design (QbD) is often associated with protocol development and study execution. However, one of the most important opportunities to improve trial quality occurs much earlier, during the selection of CROs and critical vendors. In this presentation, Vatché will discuss how sponsors can strengthen study oversight by incorporating risk-based governance, quality expectations, and operational performance criteria into partner selection from the outset. Key discussion topics include: Applying Quality-by-Design (QbD) before study start-up Risk-based approaches to CRO and vendor selection Strengthening sponsor oversight and governance Moving beyond cost-driven outsourcing decisions Building collaborative partnerships that improve trial quality Why Attend This Session? Whether you are planning your first clinical trial or managing a global development portfolio, this session will provide practical strategies for improving operational performance by making better decisions before a study begins. Meet with Vantage BioTrials Planning an upcoming clinical program? Meet with Vatché and his team to discuss how Vantage BioTrials helps biotechnology, pharmaceutical, and medical device sponsors strengthen clinical trial execution through: Clinical Trial Management Quality-by-Design (QbD) Risk-Based Quality Management (RBQM) Clinical Operations Leadership Vendor Oversight Inspection Readiness Regulatory Compliance Why Vantage BioTrials? Vantage BioTrials partners with sponsors to transform clinical development strategies into successful clinical programs through disciplined execution, proactive risk management, and collaborative operational leadership. Our experienced team works as an extension of sponsor organizations, helping identify and mitigate risks early while maintaining the highest standards of patient safety, regulatory compliance, and data integrity. Schedule a Meeting If you will be attending the 10th Operational Excellence in Clinical Trials Summit, we invite you to connect with Vatché to discuss your upcoming clinical development objectives. 📧 info@vantagebiotrials.com

The post Operational Excellence in Clinical Trials Summit | September 23 – 24, 2026 first appeared on Vantage Biotrials.

]]>
Vantage BioTrials to Present at the 10th Operational Excellence in Clinical Trials Summit

Join Vatché Bartekian for a Featured Presentation on Quality-by-Design and Risk-Based Governance

September 23–24, 2026 | Courtyard Toronto Downtown | Toronto, Canada

Vantage BioTrials is pleased to announce that Vatché Bartekian, President, has been invited to speak at the 10th Operational Excellence in Clinical Trials Summit (OECT Summit Canada 2026), one of Canada’s leading conferences dedicated to advancing innovation and operational excellence in clinical research. The summit brings together leaders in Clinical Operations, Clinical Development, Project Management, Study Feasibility, Site Management, and Vendor Oversight to explore strategies that improve clinical trial performance.


Featured Presentation

Quality by Design Begins Before Study Start-Up: Embedding Risk-Based Governance into CRO and Vendor Selection

Quality-by-Design (QbD) is often associated with protocol development and study execution. However, one of the most important opportunities to improve trial quality occurs much earlier, during the selection of CROs and critical vendors.

In this presentation, Vatché will discuss how sponsors can strengthen study oversight by incorporating risk-based governance, quality expectations, and operational performance criteria into partner selection from the outset.

Key discussion topics include:

  • Applying Quality-by-Design (QbD) before study start-up
  • Risk-based approaches to CRO and vendor selection
  • Strengthening sponsor oversight and governance
  • Moving beyond cost-driven outsourcing decisions
  • Building collaborative partnerships that improve trial quality

Why Attend This Session?

Whether you are planning your first clinical trial or managing a global development portfolio, this session will provide practical strategies for improving operational performance by making better decisions before a study begins.


Meet with Vantage BioTrials

Planning an upcoming clinical program?

Meet with Vatché and his team to discuss how Vantage BioTrials helps biotechnology, pharmaceutical, and medical device sponsors strengthen clinical trial execution through:

  • Clinical Trial Management
  • Quality-by-Design (QbD)
  • Risk-Based Quality Management (RBQM)
  • Clinical Operations Leadership
  • Vendor Oversight
  • Inspection Readiness
  • Regulatory Compliance

Why Vantage BioTrials?

Vantage BioTrials partners with sponsors to transform clinical development strategies into successful clinical programs through disciplined execution, proactive risk management, and collaborative operational leadership.

Our experienced team works as an extension of sponsor organizations, helping identify and mitigate risks early while maintaining the highest standards of patient safety, regulatory compliance, and data integrity.


Schedule a Meeting

If you will be attending the 10th Operational Excellence in Clinical Trials Summit, we invite you to connect with Vatché to discuss your upcoming clinical development objectives.

📧 info@vantagebiotrials.com

The post Operational Excellence in Clinical Trials Summit | September 23 – 24, 2026 first appeared on Vantage Biotrials.

]]>
BioHorizon | October 7 – 8, 2026 https://vantagebiotrials.com/fr/biohorizon-october-7-8-2026/?utm_source=rss&utm_medium=rss&utm_campaign=biohorizon-october-7-8-2026 Mon, 03 Aug 2026 14:02:22 +0000 https://vantagebiotrials.com/?p=5316 Vantage BioTrials to Sponsor, Exhibit & Lead a Panel at BIOHorizon 2026 Visit Us at Booth #22 and Join Our Executive Panel Discussion October 7–8, 2026 | Sheraton Laval | Laval, Québec, Canada Vantage BioTrials is proud to be a BIOHorizon 2026 Sponsor and Exhibitor (Booth #22). We are also pleased to announce that Vatché Bartekian, President, will moderate an executive panel discussion entitled: From Clinical Strategy to Execution: Delivering Successful Clinical Programs BIOHorizon is Québec’s flagship life sciences and health technologies event, bringing together biotechnology companies, pharmaceutical organizations, investors, researchers, healthcare leaders, and service providers to foster collaboration and business development. Executive Panel Discussion A successful clinical program requires more than a sound strategy, it requires disciplined execution. Join Vatché and a panel of industry experts as they discuss practical approaches to transforming clinical strategy into successful execution through: Quality-by-Design (QbD) Risk-based clinical trial management Sponsor–CRO collaboration Operational excellence Lessons learned from real-world clinical programs Visit Vantage BioTrials at Booth #22 Whether you’re preparing for your first clinical study or advancing a global development program, stop by Booth #22 to learn how Vantage BioTrials helps biotechnology, pharmaceutical, and medical device sponsors deliver successful early-late phase clinical trials through: Clinical Trial Management Quality-by-Design (QbD) Risk-Based Quality Management (RBQM) Clinical Operations Leadership Regulatory Compliance Inspection Readiness Why Vantage BioTrials? Vantage BioTrials partners with sponsors to transform clinical development strategies into successful clinical programs through disciplined execution, proactive risk management, and collaborative operational leadership. Our experienced team works as an extension of sponsor organizations, helping identify and mitigate risks early while maintaining the highest standards of patient safety, regulatory compliance, and data integrity. Let’s Connect at BIOHorizon We look forward to meeting: Biotechnology companies Pharmaceutical sponsors Medical device and diagnostics innovators Radiopharmaceutical developers Investors and strategic partners 📍 Visit Booth #22 🎤 Attend our panel discussion 📧 Schedule a meeting: info@vantagebiotrials.com About BIOHorizon Organized by BIOQuébec and Montréal InVivo, BIOHorizon is Québec’s premier life sciences and health technologies conference. The 2026 event takes place October 7–8 at the Sheraton Laval, with an International Day on October 6, bringing together leaders from across Québec, Canada, and the global life sciences ecosystem.

The post BioHorizon | October 7 – 8, 2026 first appeared on Vantage Biotrials.

]]>
Vantage BioTrials to Sponsor, Exhibit & Lead a Panel at BIOHorizon 2026

Visit Us at Booth #22 and Join Our Executive Panel Discussion

October 7–8, 2026 | Sheraton Laval | Laval, Québec, Canada

Vantage BioTrials is proud to be a BIOHorizon 2026 Sponsor and Exhibitor (Booth #22). We are also pleased to announce that Vatché Bartekian, President, will moderate an executive panel discussion entitled:

From Clinical Strategy to Execution: Delivering Successful Clinical Programs

BIOHorizon is Québec’s flagship life sciences and health technologies event, bringing together biotechnology companies, pharmaceutical organizations, investors, researchers, healthcare leaders, and service providers to foster collaboration and business development.


Executive Panel Discussion

A successful clinical program requires more than a sound strategy, it requires disciplined execution.

Join Vatché and a panel of industry experts as they discuss practical approaches to transforming clinical strategy into successful execution through:

  • Quality-by-Design (QbD)
  • Risk-based clinical trial management
  • Sponsor–CRO collaboration
  • Operational excellence
  • Lessons learned from real-world clinical programs

Visit Vantage BioTrials at Booth #22

Whether you’re preparing for your first clinical study or advancing a global development program, stop by Booth #22 to learn how Vantage BioTrials helps biotechnology, pharmaceutical, and medical device sponsors deliver successful early-late phase clinical trials through:

  • Clinical Trial Management
  • Quality-by-Design (QbD)
  • Risk-Based Quality Management (RBQM)
  • Clinical Operations Leadership
  • Regulatory Compliance
  • Inspection Readiness

Why Vantage BioTrials?

Vantage BioTrials partners with sponsors to transform clinical development strategies into successful clinical programs through disciplined execution, proactive risk management, and collaborative operational leadership.

Our experienced team works as an extension of sponsor organizations, helping identify and mitigate risks early while maintaining the highest standards of patient safety, regulatory compliance, and data integrity.


Let’s Connect at BIOHorizon

We look forward to meeting:

  • Biotechnology companies
  • Pharmaceutical sponsors
  • Medical device and diagnostics innovators
  • Radiopharmaceutical developers
  • Investors and strategic partners

📍 Visit Booth #22

🎤 Attend our panel discussion

📧 Schedule a meeting: info@vantagebiotrials.com


About BIOHorizon

Organized by BIOQuébec and Montréal InVivo, BIOHorizon is Québec’s premier life sciences and health technologies conference. The 2026 event takes place October 7–8 at the Sheraton Laval, with an International Day on October 6, bringing together leaders from across Québec, Canada, and the global life sciences ecosystem.

The post BioHorizon | October 7 – 8, 2026 first appeared on Vantage Biotrials.

]]>
BIO-Europe | November 9-11, 2026 https://vantagebiotrials.com/fr/bio-europe-november-9-11-2026/?utm_source=rss&utm_medium=rss&utm_campaign=bio-europe-november-9-11-2026 Fri, 10 Jul 2026 17:28:15 +0000 https://vantagebiotrials.com/?p=5237 Vantage BioTrials at Bio-Europe November 9–11, 2026 | Cologne, Germany Vantage BioTrials is pleased to announce that Vatché Bartekian, President, will attend BIO-Europe 2026 in Cologne, Germany. BIO-Europe is Europe’s largest and longest-running partnering conference for the global biotechnology and biopharmaceutical industry. The event is expected to bring together more than 5,800 participants representing over 3,200 companies from more than 60 countries. If your organization is preparing for a Phase I–IV clinical trial, evaluating a clinical research organization or planning an upcoming clinical development milestone, Vatché welcomes the opportunity to discuss how Vantage BioTrials can support your program through disciplined execution, proactive risk management and collaborative clinical trial leadership. Planning a clinical trial? Meet with Vantage BioTrials at BIO-Europe 2026 to discuss how our Quality-by-Design approach and structured operational oversight can help advance your development program. Why Meet with Vantage BioTrials at BIO-Europe? Selecting the right CRO involves more than outsourcing clinical trial activities. It requires a partner that can anticipate operational challenges, protect study quality and maintain clear oversight throughout the clinical development lifecycle. Vantage BioTrials combines Quality-by-Design principles, risk-based quality management and experienced clinical operations leadership to help sponsors translate development strategies into practical and reliable trial execution. Our collaborative operating model is designed to provide: Structured clinical trial governance Quality-by-Design implementation Proactive risk identification and mitigation Experienced project management and clinical monitoring Regulatory and ethics submission support Vendor oversight and performance management Inspection readiness and quality management Protection of patient safety and data integrity Whether supporting an emerging biotechnology company entering clinical development or an established sponsor managing a complex multinational study, our team works as an extension of the sponsor organization and provides solutions aligned with the needs, risks and objectives of each program. Who We Would Like to Meet Vantage BioTrials welcomes discussions with: Biotechnology companies preparing for first-in-human or early-phase studies Pharmaceutical sponsors seeking responsive and experienced CRO support Medical device and diagnostic developers Radiopharmaceutical and nuclear medicine innovators Companies considering clinical development in Canada or North America Organizations planning multinational Phase I–IV programs Investors and strategic partners supporting clinical-stage companies Clinical Trial Services and Expertise Vantage BioTrials provides clinical trial management and operational oversight services across early- and late-phase development programs. Our capabilities include: Clinical project management On-site and remote clinical monitoring Risk-Based Quality Management Site feasibility and selection Study start-up Regulatory and ethics submissions Site management and participant recruitment support Vendor oversight Trial Master File oversight Quality management and inspection readiness Medical device clinical studies Radiopharmaceutical and imaging-based trials Phase I–IV clinical development Meet Vatché Bartekian President, Vantage BioTrials With more than 28 years of experience in the pharmaceutical and biotechnology sectors, Vatché Bartekian brings extensive expertise in global drug development and the operational execution of complex clinical programs. His leadership emphasizes scientific integrity, proactive risk identification and mitigation, structured governance and disciplined trial execution. At BIO-Europe 2026, Vatché looks forward to meeting with biotechnology and pharmaceutical executives to discuss: Clinical development strategy and operational planning Risk-based approaches to complex trial execution Canadian and North American clinical development opportunities Sponsor oversight and CRO governance Quality-by-Design implementation Medical device, diagnostic and radiopharmaceutical programs Early- through late-phase clinical trial support Why Attend BIO-Europe 2026? BIO-Europe is a leading global forum for biopharmaceutical partnering. The 2026 program is expanding beyond traditional business development and investment discussions to include clinical strategy, regulatory developments and manufacturing considerations. The conference brings together biotechnology and pharmaceutical companies, investors, academic organizations and industry service providers for scheduled one-to-one meetings, educational sessions and strategic networking opportunities. Partnering meetings are facilitated through the partneringONE platform. For clinical-stage companies, the event provides an opportunity to identify potential development partners, evaluate service providers and establish relationships that can support future clinical and commercial milestones. Schedule a Meeting at BIO-Europe 2026 If you will be attending BIO-Europe 2026, we invite you to schedule a meeting with Vatché Bartekian. We would welcome the opportunity to learn about your clinical development objectives and discuss how Vantage BioTrials may support your program through experienced leadership, proactive risk management and disciplined clinical trial execution. Email: info@vantagebiotrials.com About Vantage BioTrials Vantage BioTrials is a Canadian clinical research organization specializing in clinical trial management, operational oversight, Quality-by-Design and proactive risk management. We collaborate with biotechnology, pharmaceutical and medical device sponsors to support early-late phase clinical trials while maintaining rigorous standards of patient safety, regulatory compliance and data integrity.

The post BIO-Europe | November 9-11, 2026 first appeared on Vantage Biotrials.

]]>
Vantage BioTrials at Bio-Europe

November 9–11, 2026 | Cologne, Germany

Vantage BioTrials is pleased to announce that Vatché Bartekian, President, will attend BIO-Europe 2026 in Cologne, Germany.

BIO-Europe is Europe’s largest and longest-running partnering conference for the global biotechnology and biopharmaceutical industry. The event is expected to bring together more than 5,800 participants representing over 3,200 companies from more than 60 countries.

If your organization is preparing for a Phase I–IV clinical trial, evaluating a clinical research organization or planning an upcoming clinical development milestone, Vatché welcomes the opportunity to discuss how Vantage BioTrials can support your program through disciplined execution, proactive risk management and collaborative clinical trial leadership.

Planning a clinical trial? Meet with Vantage BioTrials at BIO-Europe 2026 to discuss how our Quality-by-Design approach and structured operational oversight can help advance your development program.


Why Meet with Vantage BioTrials at BIO-Europe?

Selecting the right CRO involves more than outsourcing clinical trial activities. It requires a partner that can anticipate operational challenges, protect study quality and maintain clear oversight throughout the clinical development lifecycle.

Vantage BioTrials combines Quality-by-Design principles, risk-based quality management and experienced clinical operations leadership to help sponsors translate development strategies into practical and reliable trial execution.

Our collaborative operating model is designed to provide:

  • Structured clinical trial governance
  • Quality-by-Design implementation
  • Proactive risk identification and mitigation
  • Experienced project management and clinical monitoring
  • Regulatory and ethics submission support
  • Vendor oversight and performance management
  • Inspection readiness and quality management
  • Protection of patient safety and data integrity

Whether supporting an emerging biotechnology company entering clinical development or an established sponsor managing a complex multinational study, our team works as an extension of the sponsor organization and provides solutions aligned with the needs, risks and objectives of each program.


Who We Would Like to Meet

Vantage BioTrials welcomes discussions with:

  • Biotechnology companies preparing for first-in-human or early-phase studies
  • Pharmaceutical sponsors seeking responsive and experienced CRO support
  • Medical device and diagnostic developers
  • Radiopharmaceutical and nuclear medicine innovators
  • Companies considering clinical development in Canada or North America
  • Organizations planning multinational Phase I–IV programs
  • Investors and strategic partners supporting clinical-stage companies

Clinical Trial Services and Expertise

Vantage BioTrials provides clinical trial management and operational oversight services across early- and late-phase development programs.

Our capabilities include:

  • Clinical project management
  • On-site and remote clinical monitoring
  • Risk-Based Quality Management
  • Site feasibility and selection
  • Study start-up
  • Regulatory and ethics submissions
  • Site management and participant recruitment support
  • Vendor oversight
  • Trial Master File oversight
  • Quality management and inspection readiness
  • Medical device clinical studies
  • Radiopharmaceutical and imaging-based trials
  • Phase I–IV clinical development

Meet Vatché Bartekian

President, Vantage BioTrials

With more than 28 years of experience in the pharmaceutical and biotechnology sectors, Vatché Bartekian brings extensive expertise in global drug development and the operational execution of complex clinical programs.

His leadership emphasizes scientific integrity, proactive risk identification and mitigation, structured governance and disciplined trial execution.

At BIO-Europe 2026, Vatché looks forward to meeting with biotechnology and pharmaceutical executives to discuss:

  • Clinical development strategy and operational planning
  • Risk-based approaches to complex trial execution
  • Canadian and North American clinical development opportunities
  • Sponsor oversight and CRO governance
  • Quality-by-Design implementation
  • Medical device, diagnostic and radiopharmaceutical programs
  • Early- through late-phase clinical trial support

Why Attend BIO-Europe 2026?

BIO-Europe is a leading global forum for biopharmaceutical partnering. The 2026 program is expanding beyond traditional business development and investment discussions to include clinical strategy, regulatory developments and manufacturing considerations.

The conference brings together biotechnology and pharmaceutical companies, investors, academic organizations and industry service providers for scheduled one-to-one meetings, educational sessions and strategic networking opportunities. Partnering meetings are facilitated through the partneringONE platform.

For clinical-stage companies, the event provides an opportunity to identify potential development partners, evaluate service providers and establish relationships that can support future clinical and commercial milestones.


Schedule a Meeting at BIO-Europe 2026

If you will be attending BIO-Europe 2026, we invite you to schedule a meeting with Vatché Bartekian.

We would welcome the opportunity to learn about your clinical development objectives and discuss how Vantage BioTrials may support your program through experienced leadership, proactive risk management and disciplined clinical trial execution.

Email: info@vantagebiotrials.com


About Vantage BioTrials

Vantage BioTrials is a Canadian clinical research organization specializing in clinical trial management, operational oversight, Quality-by-Design and proactive risk management.

We collaborate with biotechnology, pharmaceutical and medical device sponsors to support early-late phase clinical trials while maintaining rigorous standards of patient safety, regulatory compliance and data integrity.

The post BIO-Europe | November 9-11, 2026 first appeared on Vantage Biotrials.

]]>
BioNJ BioPartnering | May 12, 2026 https://vantagebiotrials.com/fr/bionj-biopartnering-may-12-2026/?utm_source=rss&utm_medium=rss&utm_campaign=bionj-biopartnering-may-12-2026 Mon, 30 Mar 2026 15:05:23 +0000 https://vantagebiotrials.com/?p=4856 Vantage BioTrials at BioNJ BioPartnering 2026 Vantage BioTrials will attend the BioNJ BioPartnering Conference on May 12, 2026 in New Jersey, as part of the BioQuébec delegation. This event brings together biotechnology companies, pharmaceutical organizations, investors, and service providers. It creates a valuable setting for collaboration and discussion across the life sciences ecosystem. As clinical programs become more complex, early alignment between sponsors and CRO partners is increasingly important. As a result, strong operational planning and clear communication are essential for successful trial execution. Representing Vantage BioTrials Vatche Bartekian, President of Vantage BioTrials, will attend the conference. As a member of BioQuébec, Vantage BioTrials is pleased to join the Québec delegation once again. This participation highlights the strength of Québec’s life sciences ecosystem and its growing role in global clinical research. Full-Service Clinical Trial Management Expertise Vantage BioTrials has supported sponsors for nearly two decades. Our model focuses on structured, full-service clinical trial management. Our capabilities include: Clinical project management and oversight Risk-based monitoring Quality management systems Study start-up and site coordination Vendor oversight Management of complex and late-phase programs In addition, our approach is grounded in Quality by Design (QbD) principles. It also includes proactive risk mitigation from the earliest stages of development. Therefore, potential challenges are identified early and managed effectively throughout the study. 👉 Learn more about our therapeutic expertise. Supporting Clinical Development in a Changing Landscape Today, clinical development is evolving rapidly. Consequently, sponsors are looking for CRO partners who can provide both execution and strategic support. At BioNJ, we look forward to discussing key topics such as: Managing complexity across clinical programs Supporting lean sponsor teams Maintaining data quality and patient safety Applying structured, risk-based approaches These discussions are critical. They help ensure that promising therapies move forward efficiently while maintaining high standards. About BioNJ BioPartnering The BioNJ BioPartnering Conference is a leading life sciences event in the United States. It brings together innovators, investors, and partners to support collaboration and growth. 👉 Learn more: https://www.bionj.org/ Connect with Vantage BioTrials If you plan to attend BioNJ BioPartnering 2026, we would welcome the opportunity to connect. We would be pleased to discuss how structured clinical trial management, proactive risk mitigation, and collaborative execution can support your development programs.

The post BioNJ BioPartnering | May 12, 2026 first appeared on Vantage Biotrials.

]]>
Vantage BioTrials at BioNJ BioPartnering 2026

Vantage BioTrials will attend the BioNJ BioPartnering Conference on May 12, 2026 in New Jersey, as part of the BioQuébec delegation.

This event brings together biotechnology companies, pharmaceutical organizations, investors, and service providers. It creates a valuable setting for collaboration and discussion across the life sciences ecosystem.

As clinical programs become more complex, early alignment between sponsors and CRO partners is increasingly important. As a result, strong operational planning and clear communication are essential for successful trial execution.


Representing Vantage BioTrials

Vatche Bartekian, President of Vantage BioTrials, will attend the conference.

As a member of BioQuébec, Vantage BioTrials is pleased to join the Québec delegation once again. This participation highlights the strength of Québec’s life sciences ecosystem and its growing role in global clinical research.


Full-Service Clinical Trial Management Expertise

Vantage BioTrials has supported sponsors for nearly two decades. Our model focuses on structured, full-service clinical trial management.

Our capabilities include:

  • Clinical project management and oversight
  • Risk-based monitoring
  • Quality management systems
  • Study start-up and site coordination
  • Vendor oversight
  • Management of complex and late-phase programs

In addition, our approach is grounded in Quality by Design (QbD) principles. It also includes proactive risk mitigation from the earliest stages of development. Therefore, potential challenges are identified early and managed effectively throughout the study.

👉 Learn more about our therapeutic expertise.


Supporting Clinical Development in a Changing Landscape

Today, clinical development is evolving rapidly. Consequently, sponsors are looking for CRO partners who can provide both execution and strategic support.

At BioNJ, we look forward to discussing key topics such as:

  • Managing complexity across clinical programs
  • Supporting lean sponsor teams
  • Maintaining data quality and patient safety
  • Applying structured, risk-based approaches

These discussions are critical. They help ensure that promising therapies move forward efficiently while maintaining high standards.


About BioNJ BioPartnering

The BioNJ BioPartnering Conference is a leading life sciences event in the United States. It brings together innovators, investors, and partners to support collaboration and growth.

👉 Learn more: https://www.bionj.org/


Connect with Vantage BioTrials

If you plan to attend BioNJ BioPartnering 2026, we would welcome the opportunity to connect.

We would be pleased to discuss how structured clinical trial management, proactive risk mitigation, and collaborative execution can support your development programs.

The post BioNJ BioPartnering | May 12, 2026 first appeared on Vantage Biotrials.

]]>
SNMMI Annual Meeting | May 30 – June 2, 2026 https://vantagebiotrials.com/fr/snmmi-annual-meeting-may-30-june-2-2026/?utm_source=rss&utm_medium=rss&utm_campaign=snmmi-annual-meeting-may-30-june-2-2026 Wed, 25 Feb 2026 17:14:59 +0000 https://vantagebiotrials.com/?p=4636 Vantage BioTrials at SNMMI 2026 Vantage BioTrials will attend the Society of Nuclear Medicine and Molecular Imaging Annual Meeting (SNMMI 2026) from May 30 to June 2, 2026. This global event brings together leaders in nuclear medicine, molecular imaging, and radiopharmaceutical development. It creates a space to share scientific advances and discuss real-world applications. As innovation accelerates, clinical trial execution becomes more specialized. As a result, sponsors must rely on strong operational oversight and clear coordination. Meet the Vantage BioTrials Team Representing Vantage BioTrials at the meeting will be: Vatche Bartekian, President Viken Bartekian, Vice President, Corporate Development They look forward to connecting with sponsors, investigators, and partners working in radiopharmaceutical and imaging-based development. Radiopharmaceutical Clinical Trial Expertise Radiopharmaceutical trials require a specialized operational approach. These studies involve complex logistics, strict regulatory expectations, and coordinated site execution. At Vantage BioTrials, we support these programs through: Coordination with nuclear medicine teams and imaging sites Oversight of radiopharmaceutical handling and logistics Support for imaging endpoints and centralized review Risk-based monitoring tailored to complex protocols Collaboration with specialized clinical sites In addition, our approach is grounded in Quality by Design (QbD). It also integrates proactive risk mitigation from the earliest stages. Therefore, teams can identify risks early and manage them throughout the trial lifecycle. 👉 Learn more about our therapeutic expertise . What We’re Focused On at SNMMI Today, radiopharmaceutical development continues to evolve. Consequently, clinical programs require greater coordination and operational precision. At SNMMI, we look forward to discussing: Managing complexity in radiopharmaceutical trials Coordinating imaging infrastructure and site readiness Maintaining data quality and protocol compliance Applying structured, risk-based oversight These priorities are directly linked to successful execution. As a result, alignment between sponsors and CRO partners remains essential. About SNMMI The Society of Nuclear Medicine and Molecular Imaging Annual Meeting is a leading global conference in nuclear medicine and molecular imaging. It brings together clinicians, researchers, and industry leaders. Together, they advance innovation across diagnostics and targeted therapies. 👉 Learn more about the meeting: https://www.snmmi.org/ Connect with Vantage BioTrials If you will be attending SNMMI 2026, we welcome the opportunity to connect. We would be pleased to discuss how disciplined clinical trial management, proactive risk mitigation, and collaborative execution can support your radiopharmaceutical development programs.

The post SNMMI Annual Meeting | May 30 – June 2, 2026 first appeared on Vantage Biotrials.

]]>
Vantage BioTrials at SNMMI 2026

Vantage BioTrials will attend the Society of Nuclear Medicine and Molecular Imaging Annual Meeting (SNMMI 2026) from May 30 to June 2, 2026.

This global event brings together leaders in nuclear medicine, molecular imaging, and radiopharmaceutical development. It creates a space to share scientific advances and discuss real-world applications.

As innovation accelerates, clinical trial execution becomes more specialized. As a result, sponsors must rely on strong operational oversight and clear coordination.


Meet the Vantage BioTrials Team

Representing Vantage BioTrials at the meeting will be:

  • Vatche Bartekian, President
  • Viken Bartekian, Vice President, Corporate Development

They look forward to connecting with sponsors, investigators, and partners working in radiopharmaceutical and imaging-based development.


Radiopharmaceutical Clinical Trial Expertise

Radiopharmaceutical trials require a specialized operational approach. These studies involve complex logistics, strict regulatory expectations, and coordinated site execution.

At Vantage BioTrials, we support these programs through:

  • Coordination with nuclear medicine teams and imaging sites
  • Oversight of radiopharmaceutical handling and logistics
  • Support for imaging endpoints and centralized review
  • Risk-based monitoring tailored to complex protocols
  • Collaboration with specialized clinical sites

In addition, our approach is grounded in Quality by Design (QbD). It also integrates proactive risk mitigation from the earliest stages. Therefore, teams can identify risks early and manage them throughout the trial lifecycle.

👉 Learn more about our therapeutic expertise .


What We’re Focused On at SNMMI

Today, radiopharmaceutical development continues to evolve. Consequently, clinical programs require greater coordination and operational precision.

At SNMMI, we look forward to discussing:

  • Managing complexity in radiopharmaceutical trials
  • Coordinating imaging infrastructure and site readiness
  • Maintaining data quality and protocol compliance
  • Applying structured, risk-based oversight

These priorities are directly linked to successful execution. As a result, alignment between sponsors and CRO partners remains essential.


About SNMMI

The Society of Nuclear Medicine and Molecular Imaging Annual Meeting is a leading global conference in nuclear medicine and molecular imaging.

It brings together clinicians, researchers, and industry leaders. Together, they advance innovation across diagnostics and targeted therapies.

👉 Learn more about the meeting: https://www.snmmi.org/


Connect with Vantage BioTrials

If you will be attending SNMMI 2026, we welcome the opportunity to connect.

We would be pleased to discuss how disciplined clinical trial management, proactive risk mitigation, and collaborative execution can support your radiopharmaceutical development programs.

The post SNMMI Annual Meeting | May 30 – June 2, 2026 first appeared on Vantage Biotrials.

]]>
COG New England | April 28–29, 2026 https://vantagebiotrials.com/fr/cog-new-england-april-28-29-2026/?utm_source=rss&utm_medium=rss&utm_campaign=cog-new-england-april-28-29-2026 Wed, 25 Feb 2026 17:00:13 +0000 https://vantagebiotrials.com/?p=4622 Vantage BioTrials at COG New England 2026 Vantage BioTrials will be exhibiting at the New England Clinical Outsourcing Group (COG) conference on April 28–29, 2026 in Boston. This event brings together clinical operations leaders, sponsors, and service providers from across the life sciences industry. It provides a practical forum to discuss the realities of clinical trial execution. As clinical programs become more complex, these conversations are increasingly important. As a result, strong operational alignment and proactive planning are essential for successful outcomes. Meet the Vantage BioTrials Team Representing Vantage BioTrials at the conference will be Vatche Bartekian, President, and Viken Bartekian, VP or Corporate Development. They look forward to connecting with sponsors and industry peers to exchange perspectives on clinical operations and trial execution. Full-Service Clinical Trial Management Expertise Vantage BioTrials brings nearly two decades of experience in clinical trial management. Our model focuses on structured execution, operational oversight, and quality-driven delivery. Our capabilities include: Clinical project management and oversight Risk-based monitoring Quality management systems Study start-up and site coordination Vendor oversight and alignment Management of complex and late-phase programs In addition, our approach is grounded in Quality by Design (QbD). It also incorporates proactive risk mitigation from the earliest stages of development. As a result, risks are identified early and managed throughout the trial lifecycle. 👉 Learn more about our therapeutic expertise. What We’re Focused on at COG Today, sponsors face increasing pressure to deliver results efficiently while maintaining high standards of quality. In this context, we look forward to discussing: Managing complexity across clinical programs Supporting lean sponsor teams Maintaining data quality and patient safety Applying structured, risk-based approaches These topics are central to successful clinical trial execution. Therefore, open dialogue between sponsors and CRO partners remains essential. About COG New England The New England Clinical Outsourcing Group (COG) conference is a well-established event focused on clinical outsourcing and operations. It brings together industry stakeholders to share practical insights and best practices. 👉 Learn more about the event: https://www.thepbcgroup.com/ Visit Us at Booth #5 If you will be attending COG New England, we welcome the opportunity to connect. Visit Booth #5 to discuss how structured clinical trial management, proactive risk mitigation and collaborative execution can support your development programs.

The post COG New England | April 28–29, 2026 first appeared on Vantage Biotrials.

]]>
Vantage BioTrials at COG New England 2026

Vantage BioTrials will be exhibiting at the New England Clinical Outsourcing Group (COG) conference on April 28–29, 2026 in Boston.

This event brings together clinical operations leaders, sponsors, and service providers from across the life sciences industry. It provides a practical forum to discuss the realities of clinical trial execution.

As clinical programs become more complex, these conversations are increasingly important. As a result, strong operational alignment and proactive planning are essential for successful outcomes.


Meet the Vantage BioTrials Team

Representing Vantage BioTrials at the conference will be Vatche Bartekian, President, and Viken Bartekian, VP or Corporate Development.

They look forward to connecting with sponsors and industry peers to exchange perspectives on clinical operations and trial execution.


Full-Service Clinical Trial Management Expertise

Vantage BioTrials brings nearly two decades of experience in clinical trial management. Our model focuses on structured execution, operational oversight, and quality-driven delivery.

Our capabilities include:

  • Clinical project management and oversight
  • Risk-based monitoring
  • Quality management systems
  • Study start-up and site coordination
  • Vendor oversight and alignment
  • Management of complex and late-phase programs

In addition, our approach is grounded in Quality by Design (QbD). It also incorporates proactive risk mitigation from the earliest stages of development. As a result, risks are identified early and managed throughout the trial lifecycle.

👉 Learn more about our therapeutic expertise.


What We’re Focused on at COG

Today, sponsors face increasing pressure to deliver results efficiently while maintaining high standards of quality.

In this context, we look forward to discussing:

  • Managing complexity across clinical programs
  • Supporting lean sponsor teams
  • Maintaining data quality and patient safety
  • Applying structured, risk-based approaches

These topics are central to successful clinical trial execution. Therefore, open dialogue between sponsors and CRO partners remains essential.


About COG New England

The New England Clinical Outsourcing Group (COG) conference is a well-established event focused on clinical outsourcing and operations. It brings together industry stakeholders to share practical insights and best practices.

👉 Learn more about the event: https://www.thepbcgroup.com/


Visit Us at Booth #5

If you will be attending COG New England, we welcome the opportunity to connect.

Visit Booth #5 to discuss how structured clinical trial management, proactive risk mitigation and collaborative execution can support your development programs.

The post COG New England | April 28–29, 2026 first appeared on Vantage Biotrials.

]]>
The Site Council Leadership Forum | April 21-22, 2026 https://vantagebiotrials.com/fr/the-site-council-leadership-forum-april-21-22-2026/?utm_source=rss&utm_medium=rss&utm_campaign=the-site-council-leadership-forum-april-21-22-2026 Wed, 25 Feb 2026 16:29:27 +0000 https://vantagebiotrials.com/?p=4608 Vantage BioTrials will be attending The Site Council Leadership Forum on April 21–22, 2026 in Cary, North Carolina. On Wednesday, April 22, our President, Vatche Bartekian, will serve as a panelist in the session: “How Can We Work with Study Sponsors and CROs to Get the Revenue We Deserve When We Deserve It?” This discussion will focus on practical, solution-driven strategies to strengthen sponsor–CRO–site collaboration and improve the operational mechanics of fair, transparent, and timely site payments. If you will be attending and would like to connect with Vantage BioTrials during the Forum, we welcome the opportunity to meet.

The post The Site Council Leadership Forum | April 21-22, 2026 first appeared on Vantage Biotrials.

]]>
Vantage BioTrials will be attending The Site Council Leadership Forum on April 21–22, 2026 in Cary, North Carolina.

On Wednesday, April 22, our President, Vatche Bartekian, will serve as a panelist in the session: “How Can We Work with Study Sponsors and CROs to Get the Revenue We Deserve When We Deserve It?”

This discussion will focus on practical, solution-driven strategies to strengthen sponsor–CRO–site collaboration and improve the operational mechanics of fair, transparent, and timely site payments.

If you will be attending and would like to connect with Vantage BioTrials during the Forum, we welcome the opportunity to meet.

The post The Site Council Leadership Forum | April 21-22, 2026 first appeared on Vantage Biotrials.

]]>
SCOPE Summit | February 2-5, 2026 https://vantagebiotrials.com/fr/scope-summit-february-2-5-2026/?utm_source=rss&utm_medium=rss&utm_campaign=scope-summit-february-2-5-2026 Mon, 20 Oct 2025 13:14:00 +0000 https://vantagebiotrials.com/?p=4176 Meet Vantage BioTrials at SCOPE 2026 in Orlando! Join us in Orlando, Florida, from February 2–5, 2026, as Vantage BioTrials brings its expertise in clinical trial management to the Summit for Clinical Operations Executives (SCOPE). We’re excited to share key insights, connect with industry leaders, and explore innovative solutions shaping the future of clinical operations. To discover how we can assist with your next clinical trial, please contact us at info@vantagebiotrials.com.

The post SCOPE Summit | February 2-5, 2026 first appeared on Vantage Biotrials.

]]>
Meet Vantage BioTrials at SCOPE 2026 in Orlando!

Join us in Orlando, Florida, from February 2–5, 2026, as Vantage BioTrials brings its expertise in clinical trial management to the Summit for Clinical Operations Executives (SCOPE).

We’re excited to share key insights, connect with industry leaders, and explore innovative solutions shaping the future of clinical operations.

To discover how we can assist with your next clinical trial, please contact us at info@vantagebiotrials.com.

The post SCOPE Summit | February 2-5, 2026 first appeared on Vantage Biotrials.

]]>
COG Amsterdam | November 18–19, 2025 https://vantagebiotrials.com/fr/cog-amsterdam-november-18-19-2025/?utm_source=rss&utm_medium=rss&utm_campaign=cog-amsterdam-november-18-19-2025 Mon, 20 Oct 2025 12:57:17 +0000 https://vantagebiotrials.com/?p=4162 Join Us at Booth #23 at COG Europe in Amsterdam! We’re thrilled to be exhibiting at the 3rd Annual Clinical Outsourcing Group (COG) Europe, taking place in Amsterdam from November 18–19. Stop by Booth #23 to connect with the Vantage BioTrials team and discuss the latest trends, challenges, and innovations in clinical development. With extensive experience across both early- and late-phase clinical trials — and a strategic advantage in navigating Canada’s regulatory landscape and diverse patient populations — we support our partners in: ✔️ Reducing operational and regulatory risks✔️ Streamlining trial design and execution✔️ Ensuring global compliance✔️ Accelerating development timelines Let’s explore how Vantage BioTrials can add strategic value to your clinical programs. See you at Booth #23!

The post COG Amsterdam | November 18–19, 2025 first appeared on Vantage Biotrials.

]]>
Join Us at Booth #23 at COG Europe in Amsterdam!

We’re thrilled to be exhibiting at the 3rd Annual Clinical Outsourcing Group (COG) Europe, taking place in Amsterdam from November 18–19.

Stop by Booth #23 to connect with the Vantage BioTrials team and discuss the latest trends, challenges, and innovations in clinical development.

With extensive experience across both early- and late-phase clinical trials — and a strategic advantage in navigating Canada’s regulatory landscape and diverse patient populations — we support our partners in:

✔ Reducing operational and regulatory risks
✔ Streamlining trial design and execution
✔ Ensuring global compliance
✔ Accelerating development timelines

Let’s explore how Vantage BioTrials can add strategic value to your clinical programs.

See you at Booth #23!

The post COG Amsterdam | November 18–19, 2025 first appeared on Vantage Biotrials.

]]>
9th Annual Patient-Centered Approach to Clinical Trials Conference | Oct 28-29, 2025 https://vantagebiotrials.com/fr/9th-annual-patient-centered-approach-to-clinical-trials-conference-oct-28-29-2025/?utm_source=rss&utm_medium=rss&utm_campaign=9th-annual-patient-centered-approach-to-clinical-trials-conference-oct-28-29-2025 Wed, 15 Oct 2025 14:34:56 +0000 https://vantagebiotrials.com/?p=4144 We’re proud to announce that Vantage BioTrials will be attending the 9th Annual Patient‑Centered Approach to Clinical Trials Conference, taking place on October 28–29, 2025, in Montreal! Hosted by Colorectal Cancer Canada, this important event brings together industry leaders, patient advocates, regulators, and research networks to shape the future of patient-centric oncology trials. Our presence continues to reflect our commitment to designing and managing clinical trials that are both scientifically rigorous and truly aligned with patients’ needs and lived experiences. Placing patients at the center leads to more impactful outcomes — and ultimately, better treatments. To register, click here.

The post 9th Annual Patient-Centered Approach to Clinical Trials Conference | Oct 28-29, 2025 first appeared on Vantage Biotrials.

]]>
We’re proud to announce that Vantage BioTrials will be attending the 9th Annual Patient‑Centered Approach to Clinical Trials Conference, taking place on October 28–29, 2025, in Montreal!

Hosted by Colorectal Cancer Canada, this important event brings together industry leaders, patient advocates, regulators, and research networks to shape the future of patient-centric oncology trials.

Our presence continues to reflect our commitment to designing and managing clinical trials that are both scientifically rigorous and truly aligned with patients’ needs and lived experiences. Placing patients at the center leads to more impactful outcomes — and ultimately, better treatments.

To register, click here.

The post 9th Annual Patient-Centered Approach to Clinical Trials Conference | Oct 28-29, 2025 first appeared on Vantage Biotrials.

]]>